Metformin Reduces the Progression of Atherogenesis by Regulating the Sestrin2-mTOR Pathway in Obese and Diabetic Rats

OBJECTIVE: In previous research, we found that Sestrin2 has a strong association with plasma atherogenicity and combats the progression of atherogenesis by regulating the AMPK-mTOR pathway. Metformin, an activator of AMPK, is widely used as a first-line therapy for diabetes, but its role in preventi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sundararajan, Saravanakumar, Jayachandran, Isaivani, Pandey, Gautam Kumar, Venkatesan, Saravanakumar, Rajagopal, Anusha, Gokulakrishnan, Kuppan, Balasubramanyam, Muthuswamy, Mohan, Viswanathan, Manickam, Nagaraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Lipidology and Atherosclerosis 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10548184/
https://www.ncbi.nlm.nih.gov/pubmed/37800110
http://dx.doi.org/10.12997/jla.2023.12.3.290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10548184/
https://www.ncbi.nlm.nih.gov/pubmed/37800110
http://dx.doi.org/10.12997/jla.2023.12.3.290

Ejemplares similares